Workflow
华丽家族拟增资海和药物不超过3亿元

Group 1 - The company plans to participate in a share placement financing of Haihe Pharmaceutical with a cash investment of no more than 300 million yuan, at a subscription price of 4.75 yuan per share [1] - The maximum number of shares to be subscribed is 63,157,900, which will result in the company holding between 5% and 8.09% of Haihe Pharmaceutical's total share capital after the investment [1] - This transaction constitutes a related party transaction, as Haihe Pharmaceutical is a subsidiary of Nanjing Group, the controlling shareholder of the company [1] Group 2 - The transaction has been approved by the company's board of directors and supervisory board, but it still requires approval from the shareholders' meeting [1] - Nanjing Group currently holds approximately 11.54% of Haihe Pharmaceutical's equity [1]